Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer.

ESMO open·2025

Same author

Athena: Speciality Certificate Examination case for Paediatrics and Genetics.

Clinical and experimental dermatology·2021

Same author

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

JCO precision oncology·2019

Same author

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.

Leukemia·2017

Same author

Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.

The British journal of dermatology·2017

Same author

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Cancer treatment reviews·2017

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Targeting HSP90 for cancer therapy.

D Mahalingam¹, R Swords, J S Carew

¹Institute for Drug Development, Cancer Research and Therapy Centre at the University of Texas Health Science Centre, San Antonio, TX 78229, USA.

British Journal of Cancer

|April 30, 2009

Summary

Heat-shock proteins (HSPs) are crucial for protein folding and are elevated in cancers. Targeting heat-shock protein 90 (HSP90) can degrade cancer-driving proteins, offering a promising anticancer strategy.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Related Experiment Videos

Last Updated: Jun 23, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Area of Science:

Molecular biology
Oncology
Biochemistry

Background:

Heat-shock proteins (HSPs) function as molecular chaperones, essential for protein folding, conformation, and preventing aggregation.
Elevated HSP levels are observed in various solid tumors and hematological malignancies.
Oncogenic proteins driving cellular transformation are frequently clients of HSP90.

Purpose of the Study:

To review the HSP chaperone machinery, focusing on HSP90 structure and function.
To identify key oncogenic proteins regulated by HSP90.
To explore the therapeutic potential of HSP90 inhibition in cancer treatment.

Main Methods:

Literature review of HSP chaperone machinery.
Analysis of HSP90's role in regulating oncogenic proteins.
Discussion of signaling pathways affected by HSP90 inhibition.

Main Results:

HSP90 plays a critical role in stabilizing numerous client proteins essential for cancer cell survival and proliferation.
Inhibition of HSP90 leads to the degradation of these oncogenic client proteins.
Targeting HSP90 disrupts multiple signaling pathways implicated in carcinogenesis.

Conclusions:

HSP90 is a key regulator of oncogenic proteins and a promising therapeutic target in cancer.
Chemical inhibition of HSP90 offers a strategy to degrade oncogenic proteins and combat malignancies.
Understanding HSP90's function provides insights into novel anticancer drug development.